3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Conditions
Myasthenia Gravis
3
Interventions
Carboplatin
315
Paclitaxel
303
Cisplatin
250
Docetaxel
238
pembrolizumab
230
Gemcitabine
214
Pemetrexed
158
Capecitabine
147
Rituximab
144
Bevacizumab
142
Dexamethasone
125
Fluorouracil
121
Cyclophosphamide
102
Trastuzumab
100
Doxorubicin
96
Nivolumab
93
Prednisone
92
Oxaliplatin
90
atezolizumab
75
Leucovorin
72
durvalumab
69
130-nm albumin-bound paclitaxel
68
Injections
66
Lenalidomide
63
Irinotecan
62
Bortezomib
56
Letrozole
54
Topotecan
53
Fulvestrant
53
Drug Therapy
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
INDUSTRY
×
efgartigimod alfa
×
Clear all
NCT07217587
2026-06-05
EPIC
Janssen Research & Development, LLC
Phase 3
Recruiting
115 enrolled
NCT03770403
2023-07-14
ADAPT+
argenx
Phase 3
Completed
151 enrolled
11 charts
NCT03669588
2022-02-08
ADAPT
argenx
Phase 3
Completed
167 enrolled
18 charts